Horizon Pharma PLC (NASDAQ:HZNP) released its quarterly earnings results on Monday. The biopharmaceutical company reported $0.41 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $0.12 by $0.29, MarketWatch Earnings reports. The firm had revenue of $289.51 million for the quarter, compared to the consensus estimate of $237.01 million. Horizon Pharma PLC had a positive return on equity of 21.51% and a negative net margin of 21.26%. The firm’s quarterly revenue was up 12.5% compared to the same quarter last year. During the same quarter last year, the business posted $0.56 EPS.

Shares of Horizon Pharma PLC (NASDAQ HZNP) opened at 12.70 on Monday. The firm’s market capitalization is $2.07 billion. The stock has a 50 day moving average price of $12.12 and a 200 day moving average price of $13.85. Horizon Pharma PLC has a 12-month low of $9.45 and a 12-month high of $23.44.

A number of research firms have weighed in on HZNP. Jefferies Group LLC set a $26.00 price objective on Horizon Pharma PLC and gave the stock a “buy” rating in a research report on Wednesday, April 12th. Piper Jaffray Companies set a $17.00 price objective on Horizon Pharma PLC and gave the stock a “buy” rating in a research report on Tuesday, July 25th. Zacks Investment Research raised Horizon Pharma PLC from a “strong sell” rating to a “hold” rating in a research report on Tuesday, July 11th. BMO Capital Markets reaffirmed a “buy” rating and set a $17.00 price objective on shares of Horizon Pharma PLC in a research report on Friday, July 28th. Finally, Cantor Fitzgerald set a $13.00 price objective on Horizon Pharma PLC and gave the stock a “buy” rating in a research report on Monday, July 31st. Five investment analysts have rated the stock with a hold rating, eleven have given a buy rating and one has given a strong buy rating to the company. Horizon Pharma PLC has a consensus rating of “Buy” and a consensus price target of $19.50.

In other Horizon Pharma PLC news, Director Michael G. Grey acquired 10,000 shares of Horizon Pharma PLC stock in a transaction dated Wednesday, May 10th. The stock was acquired at an average cost of $9.48 per share, for a total transaction of $94,800.00. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available at the SEC website. Insiders own 3.20% of the company’s stock.

Several institutional investors have recently modified their holdings of the company. American Century Companies Inc. increased its position in shares of Horizon Pharma PLC by 12.4% in the first quarter. American Century Companies Inc. now owns 547,464 shares of the biopharmaceutical company’s stock valued at $8,092,000 after buying an additional 60,356 shares in the last quarter. Searle & CO. acquired a new position in shares of Horizon Pharma PLC during the first quarter valued at about $781,000. C WorldWide Group Holding A S increased its position in shares of Horizon Pharma PLC by 16.6% in the first quarter. C WorldWide Group Holding A S now owns 330,709 shares of the biopharmaceutical company’s stock valued at $4,888,000 after buying an additional 47,069 shares in the last quarter. Bowling Portfolio Management LLC acquired a new position in shares of Horizon Pharma PLC during the first quarter valued at about $616,000. Finally, Adams Diversified Equity Fund Inc. increased its position in shares of Horizon Pharma PLC by 57.7% in the first quarter. Adams Diversified Equity Fund Inc. now owns 48,100 shares of the biopharmaceutical company’s stock valued at $711,000 after buying an additional 17,600 shares in the last quarter. Institutional investors and hedge funds own 82.95% of the company’s stock.

COPYRIGHT VIOLATION WARNING: “Horizon Pharma PLC (NASDAQ:HZNP) Issues Earnings Results, Beats Estimates By $0.29 EPS” was originally reported by American Banking News and is owned by of American Banking News. If you are accessing this article on another website, it was illegally stolen and republished in violation of U.S. and international copyright law. The legal version of this article can be viewed at https://www.americanbankingnews.com/2017/08/07/horizon-pharma-plc-nasdaqhznp-issues-earnings-results-beats-estimates-by-0-29-eps.html.

Horizon Pharma PLC announced that its board has approved a stock repurchase plan on Monday, May 8th that allows the company to repurchase 1,000% of shares. This repurchase authorization allows the biopharmaceutical company to repurchase shares of its stock through open market purchases. Shares repurchase plans are generally a sign that the company’s board of directors believes its shares are undervalued.

Horizon Pharma PLC Company Profile

Horizon Pharma Public Limited Company is a biopharmaceutical company. The Company is focused on identifying, developing, acquiring and commercializing differentiated and accessible medicines that address unmet medical needs. As of December 31, 2016, the Company marketed 11 medicines through its orphan, rheumatology and primary care business units.

Earnings History for Horizon Pharma PLC (NASDAQ:HZNP)

Receive News & Ratings for Horizon Pharma PLC Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Horizon Pharma PLC and related companies with MarketBeat.com's FREE daily email newsletter.